Fully implantable subcutaneous pleural port for patient-centered management of recurrent non-malignant pleural effusions.
- 1Division of Pulmonary, Allergy, Sleep, and Respiratory Medicine, Mayo Clinic Florida, Jacksonville, FL, USA.
- 2Department of Medicine, University of Miami/Jackson Health System, Miami, FL, USA.
- 3DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Abstract
Non-malignant pleural effusions (NMPEs) significantly impact patients' quality of life and represent a growing healthcare burden. We describe an alternative, patient-centered approach for managing recurrent NMPEs: the subcutaneous pleural port catheter (SPPC) technique. We conducted a retrospective cohort study of patients with NMPEs managed with SPPC between December 2023 and February 2026. Demographic details, clinical presentation, fluid volume management, and patient-tolerability were recorded. The procedure involved placement of a pleural catheter with subcutaneous tunneling, followed by routine outpatient drainage. Eight patients met the inclusion criteria. Port placement was right-sided in four patients (50%), left-sided in three (37.5%), and bilateral in one (12.5%). The median duration of port use was 204 days [interquartile range (IQR) 129-528 days], with a median of six drainages per patient (IQR 4-20) and a median volume of 790 mL drained per session (IQR 350-1,110 mL). All patients reported a positive overall experience, characterized by symptom relief after drainage and tolerability of port in situ. SPPC appears to be a safe and feasible outpatient option for selected patients requiring chronic pleural drainage, demonstrating favorable early procedural outcomes and patient tolerability in this study. It may be particularly suitable for patients with low protein, transudative pleural effusions who require intermittent drainage every 2-8 weeks and wish to avoid an external device, irrespective of anticoagulation status. Larger randomized controlled trials are needed to assess long-term efficacy, safety, and patient reported quality of life outcomes, and to define its role in the management of nonmalignant pleural effusions.
Related
- Electrode perforation of a silicone breast implant in a subcutaneous implantable cardioverter-defibrillator carrier: A previously unreported device complication.
- Intraoperative Application of the PRAETORIAN Score to Predict Optimal Subcutaneous Implantable Cardioverter‐Defibrillator Placement
- Subcutaneous versus transvenous implantable cardioverter-defibrillator therapy: an updated systematic review and meta-analysis.
- Inappropriate Therapy of Subcutaneous Implantable Cardioverter-Defibrillator Induced by an Electrical Bath
- A Dual-Marker DNA Methylation Assay Enables High-Sensitivity Detection of Malignant Effusions Across Cancer Types.
BibTeX
@article{abiatrujillo2026fully,
title = {{Fully implantable subcutaneous pleural port for patient-centered management of recurrent non-malignant pleural effusions.}},
author = {David Abia-Trujillo and Regina M Murillo-Torres and Alanna Barrios-Ruiz and Alejandra Yu Lee-Mateus and Tatiana A Rojas-Zapata and Bryan F Vaca-Cartagena and Paola Gutierrez-Gallegos and Kelly S Robertson and Melissa C Wren and Bryan C Husta and Sebastian Fernandez-Bussy},
journal = {Journal of thoracic disease},
year = {2026},
month = oct,
doi = {10.21037/jtd-2026-2214},
url = {https://europepmc.org/article/MED/42996954},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Fully implantable subcutaneous pleural port for patient-centered management of recurrent non-malignant pleural effusions.
AU - David Abia-Trujillo
AU - Regina M Murillo-Torres
AU - Alanna Barrios-Ruiz
AU - Alejandra Yu Lee-Mateus
AU - Tatiana A Rojas-Zapata
AU - Bryan F Vaca-Cartagena
AU - Paola Gutierrez-Gallegos
AU - Kelly S Robertson
AU - Melissa C Wren
AU - Bryan C Husta
AU - Sebastian Fernandez-Bussy
PY - 2026
DA - 2026/10/20
JO - Journal of thoracic disease
DO - 10.21037/jtd-2026-2214
UR - https://europepmc.org/article/MED/42996954
AB - Non-malignant pleural effusions (NMPEs) significantly impact patients' quality of life and represent a growing healthcare burden. We describe an alternative, patient-centered approach for managing recurrent NMPEs: the subcutaneous pleural port catheter (SPPC) technique. We conducted a retrospective cohort study of patients with NMPEs managed with SPPC between December 2023 and February 2026. Demographic details, clinical presentation, fluid volume management, and patient-tolerability were recorded. The procedure involved placement of a pleural catheter with subcutaneous tunneling, followed by routine outpatient drainage. Eight patients met the inclusion criteria. Port placement was right-sided in four patients (50%), left-sided in three (37.5%), and bilateral in one (12.5%). The median duration of port use was 204 days [interquartile range (IQR) 129-528 days], with a median of six drainages per patient (IQR 4-20) and a median volume of 790 mL drained per session (IQR 350-1,110 mL). All patients reported a positive overall experience, characterized by symptom relief after drainage and tolerability of port in situ. SPPC appears to be a safe and feasible outpatient option for selected patients requiring chronic pleural drainage, demonstrating favorable early procedural outcomes and patient tolerability in this study. It may be particularly suitable for patients with low protein, transudative pleural effusions who require intermittent drainage every 2-8 weeks and wish to avoid an external device, irrespective of anticoagulation status. Larger randomized controlled trials are needed to assess long-term efficacy, safety, and patient reported quality of life outcomes, and to define its role in the management of nonmalignant pleural effusions.
SN - 2072-1439
SN - 2077-6624
ER -